General Information of Drug (ID: DMNETSX)

Drug Name
Acerogenin C Drug Info
Synonyms acerogenin C; SCHEMBL4112475
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
10040223
TTD Drug ID
DMNETSX
VARIDT Drug ID
DR00884

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bexagliflozin DMK56G0 Type 2 diabetes 5A11 Approved [2]
ISIS-SGLT2 DMDKAIC Type-2 diabetes 5A11 Phase 1 [3]
KURAIDIN DMLDUJ1 Discovery agent N.A. Investigative [4]
KURARINONE DMH0G8W Discovery agent N.A. Investigative [4]
10-methoxy-N(1)-methylburnamine-17-O-veratrate DMJW25X Discovery agent N.A. Investigative [5]
Alstiphyllanine F DMKRAEW Discovery agent N.A. Investigative [5]
Kushenol N DMY13UR Discovery agent N.A. Investigative [4]
Alstiphyllanine E DMTNQ5E Discovery agent N.A. Investigative [5]
Burnamine-17-O-3',4',5'-trimethoxybenzoate DMBO0WI Discovery agent N.A. Investigative [5]
Alstiphyllanine D DM2FLDJ Discovery agent N.A. Investigative [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
SLC5A2 messenger RNA (SLC5A2 mRNA) TTF8JAT SC5A2_HUMAN Inhibitor [1]

References

1 Cyclic diarylheptanoids as Na+-glucose cotransporter (SGLT) inhibitors from Acer nikoense. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1070-4.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
4 Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9.
5 Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158.